Valneva USA, INC.
pharmaceutical company
Based in MD
🤖
AI Overview
With $800K in lobbying spend across 14 quarterly filings, Valneva USA, INC is an active lobbying client. Their lobbying covers 1 issue area. Active from 2021 to 2023.
$800K
Total Spend
3
Years Active
1
Firms Hired
8
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $220K |
| 2022 | $260K |
| 2023 | $320K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Valneva USA, INC. disclosed contacting in their lobbying filings.
HOUSE OF REPRESENTATIVESSENATEHealth & Human Services, Dept of (HHS)Labor, Dept of (DOL)Treasury, Dept ofWhite House Office
View all agency pressure data →What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
Coverage of CDC recommended vaccines.
CDC recommended vaccines.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
The American Occupational Therapy Association, INC. (Aota)
$6.0M total spend
United Assn of Journeymen & Apprentices of the Plumbing & Pipefitting Industry
$5.7M total spend
Plasma Protein Therapeutics Association
$4.8M total spend
Redwood Holdings, LLC FKA Redwood Capital Investments
$2.7M total spend
The United States Pharmacopeial Convention
$2.6M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.